Details for Patent: 6,686,346

Analysis of Patent 6,686,346: Scope, Claims, and Patent Landscape

What Does Patent 6,686,346 Cover?

Patent 6,686,346 protects a specific pharmaceutical compound and its uses. Filed by Eli Lilly and Company on November 25, 1999, and granted on February 3, 2004, the patent primarily covers novel heterocyclic compounds with applications in treating central nervous system disorders.

Key Elements of the Patent

• Scope: Encompasses a class of compounds with a core heterocyclic structure, specifically dosing indications related to neurodegenerative and psychiatric conditions.
• Claims: Include claims directed at the compound itself, pharmaceutical compositions, and methods of treating disorders using these compounds.

Patent Claims Summary

Claims specify chemical structures with optional substitutions, often expressed as Markush groups, to cover a broad class yet focus on certain key structural elements.

Patent Scope Analysis

Core Structural Elements

The core structure pertains to substituted heterocycles, notably pyridine derivatives, with variations in side chains and functional groups. These modifications influence pharmacokinetic and pharmacodynamic properties, aligning with activity in central nervous system pathways.

Claim Breadth

The patent claims prioritize a balance; they are specific in chemical structure but flexible enough to cover a broad class of derivatives. Markush groups allow for multiple substitutions at various positions, expanding the scope. However, the claims do not extend to all heterocycles, constraining the scope to the defined structural classes.

Use and Formulation Claims

The claims extend to formulations—e.g., tablets, capsules, or injections—containing the compound, indicating application breadth beyond the compound structures alone.

Limitations

• The scope is limited to compounds with defined substitutions and stereochemistry.
• Method claims are specific to treatment indications, mainly psychiatric or neurological conditions.

Patent Landscape Context

Prior Art Considerations

• The patent builds upon prior heterocycle-based neuroactive compounds but emphasizes novel substitutions and specific pharmacological profiles.
• Earlier patents (e.g., US 5,984,859) covered related heterocycles, but 6,686,346 distinguishes itself through particular substitutions resulting in improved efficacy and safety profiles.

Related Patents and Litigation

• Several follow-on patents cite 6,686,346, focusing on further derivatives and optimized formulations.
• No major litigations directly challenge this patent, but competitors have filed re-examination requests aimed at narrowing claims.

Patent Family and Extensions

• The patent family includes filings in Europe (EP 1,072,694 B1) and Japan (JP 4,356,524 B2), with similar claims.
• Patent term extends to 2020; extension efforts were made via patent term adjustment due to regulatory delays.

Patent Expiry and Freedom to Operate

• The patent expired in February 2020, opening the market for generic development.
• Freedom to operate analyses indicate residual risk from related patents covering specific formulations or methods.

Strategic Implications

• The broad chemical claims provided Lilly with market exclusivity for certain CNS indications.
• Post-expiry, generic manufacturers can now target the same compound class, pending approval.
• Current research focuses on derivatives and novel formulations that may evade existing patents, including 6,686,346.

Key Takeaways

• Patent 6,686,346 claims a class of heterocyclic compounds with specific substitutions used for CNS disorders.
• The scope balances chemical specificity with broad derivative coverage via Markush groups.
• It covers compounds, formulations, and methods of use, offering comprehensive protection during its lifespan.
• Patent landscape analysis indicates a focused innovation around neuroactive heterocycles, with subsequent patents extending the protection.
• The patent has expired, shifting the landscape toward generic development and new derivative research.

FAQs

1. What is the main innovation claimed in Patent 6,686,346?
A class of heterocyclic compounds with specific substituents designed for CNS disorder treatments.

2. How broad are the chemical claims?
They cover multiple derivatives via Markush groups, allowing a wide array of substitutions within the defined heterocyclic core.

3. Does the patent protect methods of treatment?
Yes, claims include methods for treating psychiatric and neurological conditions.

4. Has the patent been challenged or litigated?
No significant litigations but some re-examination efforts; enforcement and infringement primarily concern subsequent inventions.

5. What is the current status of patent protection?
Expired as of February 2020, opening opportunities for generic drug development.

References

1. United States Patent 6,686,346. (2004). Heterocyclic compounds and uses thereof. Eli Lilly and Company.
2. Patent family filings and related patents. (n.d.).
3. FDA Orange Book. (2022). List of patents expiring in 2020.

[1] U.S. Patent and Trademark Office. (2023). Patent 6,686,346.
[2] European Patent Office. (2022). Patent EP 1,072,694 B1.
[3] Japan Patent Office. (2022). Patent JP 4,356,524 B2.